592 related articles for article (PubMed ID: 11812518)
21. Opioid and cannabinoid modulation of precipitated withdrawal in delta(9)-tetrahydrocannabinol and morphine-dependent mice.
Lichtman AH; Sheikh SM; Loh HH; Martin BR
J Pharmacol Exp Ther; 2001 Sep; 298(3):1007-14. PubMed ID: 11504797
[TBL] [Abstract][Full Text] [Related]
22. The cannabinoid agonist HU-210: pseudo-irreversible discriminative stimulus effects in rhesus monkeys.
Hruba L; McMahon LR
Eur J Pharmacol; 2014 Mar; 727():35-42. PubMed ID: 24486701
[TBL] [Abstract][Full Text] [Related]
23. Pharmacological evaluation of aerosolized cannabinoids in mice.
Lichtman AH; Peart J; Poklis JL; Bridgen DT; Razdan RK; Wilson DM; Poklis A; Meng Y; Byron PR; Martin BR
Eur J Pharmacol; 2000 Jul; 399(2-3):141-9. PubMed ID: 10884513
[TBL] [Abstract][Full Text] [Related]
24. Behaviorally active doses of the CB1 receptor antagonist SR 141716A increase brain serotonin and dopamine levels and turnover.
Darmani NA; Janoyan JJ; Kumar N; Crim JL
Pharmacol Biochem Behav; 2003 Jul; 75(4):777-87. PubMed ID: 12957219
[TBL] [Abstract][Full Text] [Related]
25. SR 141716A differentially attenuates the behavioral effects of delta9-THC in rhesus monkeys.
McMahon LR; Amin MR; France CP
Behav Pharmacol; 2005 Sep; 16(5-6):363-72. PubMed ID: 16148440
[TBL] [Abstract][Full Text] [Related]
26. Antiemetic and motor-depressive actions of CP55,940: cannabinoid CB1 receptor characterization, distribution, and G-protein activation.
Darmani NA; Sim-Selley LJ; Martin BR; Janoyan JJ; Crim JL; Parekh B; Breivogel CS
Eur J Pharmacol; 2003 Jan; 459(1):83-95. PubMed ID: 12505537
[TBL] [Abstract][Full Text] [Related]
27. Opioid and cannabinoid receptor-mediated regulation of the increase in adrenocorticotropin hormone and corticosterone plasma concentrations induced by central administration of delta(9)-tetrahydrocannabinol in rats.
Manzanares J; Corchero J; Fuentes JA
Brain Res; 1999 Aug; 839(1):173-9. PubMed ID: 10482810
[TBL] [Abstract][Full Text] [Related]
28. Assessment of anandamide interaction with the cannabinoid brain receptor: SR 141716A antagonism studies in mice and autoradiographic analysis of receptor binding in rat brain.
Adams IB; Compton DR; Martin BR
J Pharmacol Exp Ther; 1998 Mar; 284(3):1209-17. PubMed ID: 9495885
[TBL] [Abstract][Full Text] [Related]
29. Reversal of cannabinoids (delta9-THC) by the benzoflavone moiety from methanol extract of Passiflora incarnata Linneaus in mice: a possible therapy for cannabinoid addiction.
Dhawan K; Kumar S; Sharma A
J Pharm Pharmacol; 2002 Jun; 54(6):875-81. PubMed ID: 12079005
[TBL] [Abstract][Full Text] [Related]
30. SR 141716A acts as an inverse agonist to increase neuronal voltage-dependent Ca2+ currents by reversal of tonic CB1 cannabinoid receptor activity.
Pan X; Ikeda SR; Lewis DL
Mol Pharmacol; 1998 Dec; 54(6):1064-72. PubMed ID: 9855635
[TBL] [Abstract][Full Text] [Related]
31. (R)-Methanandamide and delta9-tetrahydrocannabinol-induced operant rate decreases in rats are not readily antagonized by SR-141716A.
Järbe TU; Lamb RJ; Liu Q; Makriyannis A
Eur J Pharmacol; 2003 Apr; 466(1-2):121-7. PubMed ID: 12679148
[TBL] [Abstract][Full Text] [Related]
32. Delta-9-tetrahydrocannabinol differentially suppresses emesis versus enhanced locomotor activity produced by chemically diverse dopamine D2/D3 receptor agonists in the least shrew (Cryptotis parva).
Darmani NA; Crim JL
Pharmacol Biochem Behav; 2005 Jan; 80(1):35-44. PubMed ID: 15652378
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of agonist-antagonist properties of nitrogen mustard and cyano derivatives of delta 8-tetrahydrocannabinol.
Wiley JL; Compton DR; Gordon PM; Siegel C; Singer M; Dutta A; Lichtman AH; Balster RL; Razdan RK; Martin BR
Neuropharmacology; 1996; 35(12):1793-804. PubMed ID: 9076759
[TBL] [Abstract][Full Text] [Related]
34. The cannabinoid receptor antagonist SR-141716A induces penile erection in male rats: involvement of paraventricular glutamic acid and nitric oxide.
Melis MR; Succu S; Mascia MS; Sanna F; Melis T; Castelli MP; Argiolas A
Neuropharmacology; 2006 Feb; 50(2):219-28. PubMed ID: 16288932
[TBL] [Abstract][Full Text] [Related]
35. Characterization and distribution of binding sites for [3H]-SR 141716A, a selective brain (CB1) cannabinoid receptor antagonist, in rodent brain.
Rinaldi-Carmona M; Pialot F; Congy C; Redon E; Barth F; Bachy A; Brelière JC; Soubrié P; Le Fur G
Life Sci; 1996; 58(15):1239-47. PubMed ID: 8614277
[TBL] [Abstract][Full Text] [Related]
36. HU-308: a specific agonist for CB(2), a peripheral cannabinoid receptor.
Hanus L; Breuer A; Tchilibon S; Shiloah S; Goldenberg D; Horowitz M; Pertwee RG; Ross RA; Mechoulam R; Fride E
Proc Natl Acad Sci U S A; 1999 Dec; 96(25):14228-33. PubMed ID: 10588688
[TBL] [Abstract][Full Text] [Related]
37. Permissive role of dopamine D(2) receptors in the hypothermia induced by delta(9)-tetrahydrocannabinol in rats.
Nava F; Carta G; Gessa GL
Pharmacol Biochem Behav; 2000 May; 66(1):183-7. PubMed ID: 10837859
[TBL] [Abstract][Full Text] [Related]
38. Chronic Δ⁹-tetrahydrocannabinol treatment in rhesus monkeys: differential tolerance and cross-tolerance among cannabinoids.
McMahon LR
Br J Pharmacol; 2011 Mar; 162(5):1060-73. PubMed ID: 21091643
[TBL] [Abstract][Full Text] [Related]
39. Rapid tolerance to Delta(9)-tetrahydrocannabinol and cross-tolerance between ethanol and Delta(9)-tetrahydrocannabinol in mice.
da Silva GE; Morato GS; Takahashi RN
Eur J Pharmacol; 2001 Nov; 431(2):201-7. PubMed ID: 11728426
[TBL] [Abstract][Full Text] [Related]
40. Tolerance and cross-tolerance to cannabinoids in mice: schedule-controlled responding and hypothermia.
Singh H; Schulze DR; McMahon LR
Psychopharmacology (Berl); 2011 Jun; 215(4):665-75. PubMed ID: 21246187
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
